NEWSTIER

Mon, Aug 31
Status: JUNE AliveWelcome: Visitordata 27s old

Latest Headlines

369 categorized of 959
MIDNIGHT_TRADER12:381m agobearish

--Nvidia to Invest $3.5 Billion in MediaTek as Part of Deeper Collaboration

--Nvidia to Invest $3.5 Billion in MediaTek as Part of Deeper Collaboration | 08:38 AM EDT, 08/31/2026 (MT Newswires) -- http://www.mtnewswires.com Copyright © 2026 MT Newswires. All rights reserved. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.
TECH/AI / AI & SEMICONDUCTORS
BENZINGA12:353m agobullish

NeoVolta's NeoVolta Power Subsidiary Signs Five-Year Partnership With SK On For 9 Gigawatt-Hours Of Locally Produced Lithium Iron Phosphate Battery Cells To NeoVolta Power From 2027 To 2031

NeoVolta's NeoVolta Power Subsidiary Signs Five-Year Partnership With SK On For 9 Gigawatt-Hours Of Locally Produced Lithium Iron Phosphate Battery Cells To NeoVolta Power From 2027 To 2031 | 8:35 AM EDT, August 31, 2026 (Benzinga Newswire) NeoVolta Inc. (NASDAQ: NEOV) ("NeoVolta" or the "Company")…
PR_NEWS_WIRE12:354m agobullish

EQB to Host Investor Day 2026

EQB to Host Investor Day 2026 | TORONTO, Aug. 31, 2026 /PRNewswire/ -- EQB Inc. (TSX: EQB) today announced it will host its Investor Day 2026 on Monday, December 7, 2026, with presentations from Chadwick Westlake, President and CEO, and EQB's executive leadership team on the company's vision to rem…
BENZINGA12:345m agobearish

NanoViricides Advances NV-387 Measles Treatment Toward Phase II Trials Following FDA Rare Pediatric Disease Designation

NanoViricides Advances NV-387 Measles Treatment Toward Phase II Trials Following FDA Rare Pediatric Disease Designation | 8:34 AM EDT, August 31, 2026 (Benzinga Newswire) NanoViricides, Inc., a publicly traded company (NYSE:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the…
REGULATORY & CLINICAL / CLINICAL TRIALREGULATORY & CLINICAL / FDA/APPROVAL
BENZINGA12:345m agobullish

Endovia Health Sciences Announces U.S. Drug Enforcement Administration’s Decision To Transfer Marijuana From Schedule I To Schedule II Of Controlled Substances Act; Co. Plans To File Pre-Submission Conference With FDA For CannEpil

Endovia Health Sciences Announces U.S. Drug Enforcement Administration’s Decision To Transfer Marijuana From Schedule I To Schedule II Of Controlled Substances Act; Co. Plans To File Pre-Submission Conference With FDA For CannEpil | 8:34 AM EDT, August 31, 2026 (Benzinga Newswire) Endovia Health Sc…
REGULATORY & CLINICAL / FDA/APPROVALWEIRD / CULT/BUZZ
BENZINGA12:335m ago

Standard Lithium And Equinor's Smackover Lithium Announces Binding 10-Year Take-Or-Pay Offtake Agreement With LG Energy Solution For 8,000 Metric Tonnes Per Year Of Battery-Quality Lithium Carbonate From South West Arkansas Project; Pricing Not Disclosed

Standard Lithium And Equinor's Smackover Lithium Announces Binding 10-Year Take-Or-Pay Offtake Agreement With LG Energy Solution For 8,000 Metric Tonnes Per Year Of Battery-Quality Lithium Carbonate From South West Arkansas Project; Pricing Not Disclosed |
COMPANY NEWS / PARTNERSHIP/COLLAB
BENZINGA12:335m ago

Argus Research Maintains Buy on Salesforce, Raises Price Target to $300

Argus Research Maintains Buy on Salesforce, Raises Price Target to $300 | 8:33 AM EDT, August 31, 2026 (Benzinga Newswire) Argus Research analyst Joseph Bonner maintains Salesforce (NYSE:CRM) with a Buy and raises the price target from $290 to $300. Write to Benzinga at editorial@benzinga.com
ANALYST ACTIONS / TARGET/MAINTAINANALYST ACTIONS / UPGRADE
PR_NEWS_WIRE12:336m agobullish

Disney Springs® Resort Area Hotels Extend Fantastic Fall Rate Starting at $125

Disney Springs® Resort Area Hotels Extend Fantastic Fall Rate Starting at $125 | Stay close to the magic of the EPCOT International Food & Wine Festival LAKE BUENA VISTA, Fla., Aug. 31, 2026 /PRNewswire/ -- Travelers seeking a flavorful fall retreat at Walt Disney World Resort can find special rate…
BENZINGA12:326m ago

Lexicon Pharmaceuticals Says Post Hoc Analysis Of Phase 3 SOLOIST-WHF Trial Shows Sotagliflozin Reduced Cardiovascular Deaths, Heart Failure Events Regardless Of Baseline Systolic Blood Pressure, Without Increase In Hypotension Or Acute Kidney Injury

Lexicon Pharmaceuticals Says Post Hoc Analysis Of Phase 3 SOLOIST-WHF Trial Shows Sotagliflozin Reduced Cardiovascular Deaths, Heart Failure Events Regardless Of Baseline Systolic Blood Pressure, Without Increase In Hypotension Or Acute Kidney Injury |
REGULATORY & CLINICAL / CLINICAL TRIAL
BENZINGA12:327m agobearish

Argus Research Reiterates Hold on Canadian National Railwayto Hold

Argus Research Reiterates Hold on Canadian National Railwayto Hold | 8:32 AM EDT, August 31, 2026 (Benzinga Newswire) Argus Research analyst Kristina Ruggeri reiterates Canadian National Railway (NYSE:CNI) from Hold to Hold. Write to Benzinga at editorial@benzinga.com
ANALYST ACTIONS / TARGET/MAINTAIN